Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s DiseaseMar 2023
Non-Alcoholic SteatohepatitisApr 2023
Metachromatic LeukodystrophySep 2023
Sickle Cell DiseaseJun 2023
ICER will release our Draft Evidence Report on exagamglogene autotemcel (“exa-cel”, Vertex Pharmaceuticals and CRISPR Therapeutics) and lovotibeglogene autotemcel (“lovo-cel”, bluebird bio) for the treatment of sickle cell disease.
The Draft Report will be open to public comment until May 9th.
After about one month of receiving public comments, ICER will publish a revised Evidence Report assessing the comparative clinical effectiveness and value of resmetirom (Madrigal Pharmaceuticals, Inc.) and obeticholic acid (Ocaliva®, Intercept Pharmaceuticals, Inc.) for non-alcoholic steatohepatitis (NASH).
At ICER’s 3/17 public meeting on Leqembi for Alzheimer’s disease, ICER’s independent appraisal committee reviewed the evidence, heard further testimony from stakeholders, and deliberated over the treatment’s comparative clinical effectiveness, other potential benefits, and long-term value for money.
Please find the public meeting recordings below:
ICER’s Final Report and Meeting Summary will be available on 4/17.
Featured News & Insights.
Learn about our latest work.
ICER Names Linda Goler Blount, MPH, to Governance Board
National leader on public policy and health equity will guide ICER in its mission to achieve a health system in which all patients benefit from fair pricing, fair access, and future innovation.03/20/2023
ICER Publishes White Paper on Using Comparative Effectiveness Research to Address Prescription Drug Spending in California
State policymakers and purchasers in California are uniquely positioned to further integrate comparative effectiveness research into insurance benefit design, formulary development, and price negotiation to ensure all patients have access to effective treatments at a fair price.03/16/2023
ICER Publishes White Paper Recommending Health Technology Assessment Methods that Support Health Equity
Informed by expert Advisory Group and input from external stakeholders, White Paper highlights ongoing need to develop and test new methods for HTA groups in the US and internationally.03/15/2023
Our Origin Story.
ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
In 2021, we celebrated our 15th anniversary! Learn more.
We recently published a commentary in Health Affairs about one-time treatments like Zynteglo and Hemgenix. In both of these ICER reports, we analyzed a “shared savings” scenario, which suggests how manufacturers of these one-time therapies, instead of capturing all the avoided downstream medical costs in one giant price tag, could set a lower price and therefore share the innovation windfall with society. Read the full article here.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.
Easy access to our latest policy papers
Barriers to Fair Access
Second annual scorecard of barriers to fair access criteria; during ICER’s assessment, five payers revised policies for 11 drugs in ways that bring coverage into concordance with fair access criteria, demonstrating that assessment and greater transparency may lead to positive change
Unsupported Price Increases
Seven out of 10 high-expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.
Additionally, three Medicare Part B drugs with high list price increases in 2020 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $3,200 per year.
Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.